Xtant Medical has announced the commercial availability of its new demineralised bone matrix (DBM) allograft product, Trivium, for spinal, orthopaedic and wound care procedures.
The product is now distributed through the company’s network of independent agents operating across the US.
Trivium has been developed using Xtant Medical’s proprietary PureLoc Fibre Technology. The composition features a porous configuration designed to facilitate cell attachment and proliferation, which supports the regeneration of tissue in grafting procedures.
The allograft also undergoes the company’s BacteRinse processing method, which Xtant Medical states has been in clinical use for over 20 years. This method retains bone morphogenetic proteins (BMPs), which are essential in initiating and supporting bone formation.
Xtant Medical president and CEO Sean Browne said: “Trivium represents a significant advancement in bone grafting technology.
“By combining enhanced composition, high BMP retention, and versatile handling characteristics, Trivium provides surgeons with a dependable solution for a variety of surgical applications. We are confident that Trivium will deliver consistent, reliable outcomes for patients.”
According to the company, the product has been designed for efficient placement during surgery and is suitable for a range of applications, with features intended to assist in operative handling.
Last month, Xtant Medical released its financial results for the fourth quarter and full year ending 31 December 2024. Quarterly revenue stood at $31.5m, representing an increase of 12% from the same period in 2023.
Gross margin during the quarter declined to 50.8% from 61% a year earlier.
The company recorded a net loss of $3.2m for the fourth quarter, compared with a loss of $4.3m during the corresponding period the previous year. Adjusted EBITDA reached $438,000, up from a loss of $695,000.
For the full year, revenue totalled $117.3m, rising 28% compared to 2023. Full-year gross margin decreased to 58.2% from 60.8% the previous year.
Xtant Medical reported a net loss of $16.4m for 2024, following a net income of $660,000 in 2023. The prior-year profit included an $11.7m bargain purchase gain from the acquisition of Surgalign.
Adjusted EBITDA for the year showed a loss of $2.3m, compared to a $1.4m loss in 2023.
